Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: liraglutide

Study type: Observational

Funder types: Industry

Identifiers

NCT01821846

NN2211-3929

U1111-1132-2221 (Other Identifier)

Details and patient eligibility

About

This trial is conducted in Asia. The aim of this study is to investigate the safety profile of liraglutide (Victoza®) under normal conditions of use in Korean subjects with type 2 diabetes mellitus.

Enrollment: 64 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with T2DM (Type 2 Diabetes Mellitus), including newly-diagnosed subjects, who require treatment with Victoza® according to the clinical judgment of their treating physician
• Subjects (and/or parents or the subject's legally acceptable representative) who are capable of giving study-specific signed informed consent before any collection of information

Exclusion criteria

• Subjects with a hypersensitivity to Victoza® or to any of the excipients
• Subjects who are pregnant, breast feeding or have the intention of becoming pregnant within the study periods
• Subjects with personal or family history of medullary thyroid carcinoma (MTC)
• Subjects with multiple endocrine neoplasia syndrome type 2 (MEN2)

Trial design

64 participants in 1 patient group

Liraglutide

Treatment:

Drug: liraglutide